Obiltoxaximab
Paul G. Auwaerter, M.D.
,
Kathryn Dzintars, PharmD, BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Treatment of
inhalational anthrax
due to
Bacillus anthracis
(in combination with appropriate antibacterial drugs)
Prevention of
inhalational anthrax
when alternative agents are unavailable
CDC guidance: Choose a single antitoxin if no antimicrobial drugs are available.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.